Dual antithrombotic therapy for 1 month followed up with direct oral anticoagulant (DOAC) monotherapy for the treatment of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) is noninferior to 12 months of therapy in all-cause death and thromboembolic events, results from the OPTIMA-AF trial show.